Protein-bound polysaccharide decreases invasiveness and proliferation in pancreatic cancer by inhibition of hedgehog signaling and HIF-1α pathways under hypoxia

Cancer Letters

Volumn 335, Issue 2, 2013, Pages 289-298

  Onishi, Hideya ^a   Morisaki, Takafumi ^a   Nakao, Fumihiko ^a   Odate, Seiichi ^a   Morisaki, Takashi ^b   Katano, Mitsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Fukuoka General Cancer Clinic   (Japan)

Author keywords

Hedgehog signaling; Hh; HIF; HIF 1 ; Hypoxia; MMP; Pancreatic cancer; PDAC; PSK; Smo

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; KRESTIN; SMALL INTERFERING RNA; SONIC HEDGEHOG PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREAS DUCTAL ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR INVASION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, PANCREATIC DUCTAL; CELL CYCLE; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HEDGEHOG PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; POLYSACCHARIDES; PROTEOGLYCANS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ERINACEIDAE;

EID: 84878263855     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.02.041     Document Type: Article

References (34)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics. CA-A Cancer Journal for Clinicians 2009, 59:225-249.
2. Koong A.C., Mehta V.K., Le Q.T., Fisher G.A., Terris D.J., Brown J.M., Bastidas A.J., Vierra M. Pancreatic tumors show levels of hypoxia. International Journal of Radiation Oncology Biology Physics 2000, 48:919-922.
3. Fujiwara S., Nakagawa K., Harada H., Nagato S., Furukawa K., Teraoka M., Seno T., Oka K., Iwata S., Ohnishi T. Silencing hypoxia-inducible factor-1α inhibits cell migration and invasion under hypoxic environment in malignant gliomas. International Journal of Oncology 2007, 30:793-802.
4. Liao S.H., Zhao X.Y., Han Y.H., Zhang J., Wang L.S., Xia L., Zhao K.W., Zheng Y., Guo M., Chen G.Q. Proteomics-based identification of two novel direct targets of hypoxia-inducible factor-1 and their potential roles in migration/invasion of cancer cells. Proteomics 2009, 9:3901-3912.
5. Thangasamy A., Rogge J., Ammanamanchi S. Receptor d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1a-mediated invasion of breast carcinoma cells. The Journal of Biological Chemistry 2009, 284:14001-14010.
6. Adams J.M., Difazio L.T., Rolandelli R.H., Luján J.J., Haskó G., Csóka B., Selmeczy Z., Németh Z.H. HIF-1: a key mediator in hypoxia. Acta Physiologica Hungarica 2009, 96:19-28.
7. Ingham P.W., McMahon A.P. Hedgehog signaling in animal development: paradigms and principles. Genes and Development 2001, 15:3059-3087.
8. Cohen M.M. The hedgehog signaling network. American Journal of Medical Genetics Part A 2003, 123A:5-28.
9. Onishi H., Kai M., Odate S., Iwasaki H., Morifuji Y., Ogino T., Morisaki T., Nakashima Y., Katano M. Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer. Cancer Science 2011, 102:1144-1150.
10. Pasca di Magliano M., Hebrok M. Hedgehog signaling in cancer formation and maintenance. Nature Reviews Cancer 2003, 3:903-911.
11. Nagai S., Nakamura M., Yanai K., Wada J., Akiyoshi T., Nakashima H., Ohuchida K., Sato N., Tanaka M., Katano M. Gli1 contributes to the invasiveness of pancreatic cancer through matrix metalloproteinase-9 activation. Cancer Science 2008, 99:1377-1384.
12. Souzaki M., Kubo M., Kai M., Kameda C., Tanaka H., Taguchi T., Tanaka M., Onishi H., Katano M. Hedgehog signaling pathway mediates the progression of non-invasive breast cancer to invasive breast cancer. Cancer Science 2011, 102:373-381.
13. Onishi H., Katano M. Hedgehog signaling pathway as a therapeutic target in various types of cancer. Cancer Science 2011, 102:1756-1760.
14. Tremblay M.R., Nesler M., Weatherhead R., Castro A.C. Recent patents for hedgehog pathway inhibitors for the treatment of malignancy. Expert Opinion on Therapeutic Patents 2009, 19:1039-1056.
15. Rudin C.M., Hann C.L., Laterra J., Yauch R.L., Callahan C.A., Fu L., Holcomb T., Stinson J., Gould S.E., Coleman B., LoRusso P.M., von Hoff D.D., de Sauvage F.J., Low J.A. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. The New England Journal of Medicine 2009, 361:1173-1178.
16. Tremblay M.R., Lescarbeau A., Grogan M.J. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). Journal of Medical Chemistry 2009, 52:4400-4418.
17. Low J.A., de Sauvage F.J. Clinical experience with hedgehog pathway inhibitors. Journal of Clinical Oncology 2010, 28:5321-5326.
18. Ohno R., Imai K., Yokomaku S., Yamada K. Antitumor effect of protein-bound polysaccharide preparation, PSK, against 3-methylcholanthrene-induced fibrosarcoma in C57BL/6 mice. Gann 1975, 66:679-681.
19. Anai H., Sakaguchi Y., Emi Y., Kohnoe S., Maehara Y., Sugimachi K. A protein-bound polysaccharide immunomodulator, PSK, does not suppress the conversion from 1-(2-tetrahydrofuryl)-5-fluorouracil to 5-fluorouracil in patients with gastric cancer. Anticancer Drug 1991, 2:275-278.
20. Ebina T., Murata K. Antitumor effect of PSK at a distant site: tumor-specific immunity and combination with other chemotherapeutic agents. Japanese Journal of Cancer Research 1992, 83:775-782.
21. Iino Y., Takai Y., Sugamata N., Morishita Y. PSK (krestin) potentiates chemotherapeutic effects of tamoxifen on rat mammary carcinomas. Anticancer Research 1992, 12:2101-2103.
22. Iwaguchi T., Shimizu M., Hayashi H. Analysis of electrophoretic mobility histograms of mouse splenocytes and thymocytes during tumor growth and after combined chemotherapy and immunotherapy. Journal of Biochemical and Biophysical Methods 1989, 18:157-166.
23. Mori H., Mihara M., Teshima K., Uesugi U., Xu Q., Sakamoto O., Koda A. Effect of immunostimulants and antitumor agents on tumor necrosis factor (TNF) production. International Journal of Immunopharmacology 1987, 9:881-892.
24. Shibata M., Nezu T., Kanou H., Nagata Y., Kimura T., Takekawa M., Ando K., Fukuzawa M. Immunomodulatory effects of low dose cis-Diaminedichloroplatinum (cisplatin) combined with UFT and PSK in patients with advanced colorectal cancer. Cancer Investigation 2002, 20:166-173.
25. Takahashi Y., Mai M. Chemotherapy by combination of low-dose CPT-11 and PSK in an elderly man with liver metastasis from gastric cancer. Gan To Kagaku Ryoho (Japanese) 2001, 28:531-534.
26. Yamasaki A., Shoda M., Iijima H., Nagai S., Wada J., Suzuki H., Chikazawa N., Tasaka T., Kameda C., Tanaka H., Ikebe M., Jo E., Sato N., Nakamura M., Sekine F., Morisaki T., Katano M. A protein-bound polysaccharide, PSK, enhances tumor suppression induced by docetaxel in a gastric cancer xenograft model. Anticancer Research 2009, 29:843-850.
27. Zhang H., Morisaki T., Matsunaga H., Sato N., Uchiyama A., Hashizume K., Nagumo F., Tadano J., Katano M. Protein-bound polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-β1 and MMPs. Clinical and Experimental Metastasis 2000, 18:343-352.
28. Jiménez-Medina E., Berruguilla E., Romero I., Algarra I., Collado A., Garrido F., Garcia-Lora A. The immunomodulator PSK induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosis. BMC Cancer 2008, 8:78.
29. Hirahara N., Edamatsu T., Fujieda A., Fujioka M., Wada T., Tajima Y. Protein-bound polysaccharide-K (PSK) induces apoptosis via p38 mitogen-activated protein kinase pathway in promyelomonocytic leukemia HL-60 cells. Anticancer Research 2012, 32:2631-2637.
30. Umehara S., Fujiwara H., Shiozaki A., Todo M., Furutani A., Yoneda M., Ikai A., Tada H., Komatsu S., Ichikawa D., Okamoto K., Ochiai T., Kokuba Y., Otsuji E. PSK induces apoptosis through the inhibition of activated STST3 in human esophageal varcinoma cells. International Journal of Oncology 2012, 41:61-66.
31. Onishi H., Morifuji Y., Kai M., Suyama K., Iwasaki H., Katano M. Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer. Cancer Science 2012, 103:1272-1279.
32. Zhang H., Morisaki T., Nakahara C., Matsunaga H., Sato N., Nagumo F., Tadano J., Katano M. PSK-mediated NF-κB inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1. Oncogene 2003, 22:2088-2096.
33. Rius J., Guma M., Schachtrup C., Akassoglou K., Zinkernagel A.S., Nizet V., Johnson R.S., Haddad G.G., Karin M. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008, 453:807-811.
34. Copple B.L. Hypoxia stimulates hepatocyte epithelial to mesenchymal transition by hypoxia-inducible factor and transforming growth factor-beta-dependent mechanisms. Liver International 2010, 30:669-682.